Extremely aggressive course in a poorly differentiated thyroid carcinoma presenting a double mutation of the TERT promoter

被引:0
|
作者
Zantut-Wittmann, D. E. [1 ,7 ]
Laus, A. C. [2 ]
Moreno, D. A. [2 ]
Barreto, I. S. [3 ]
Moma, C. A. [1 ]
Maia, F. F. R. [1 ]
Etchebehere, E. C. S. C. [4 ]
Assumpcao, L. V. M. [1 ]
Reis, R. M. [2 ,5 ,6 ]
机构
[1] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, Endocrinol Div, Campinas, SP, Brazil
[2] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP, Brazil
[3] Univ Estadual Campinas, Sch Med Sci, Dept Pathol, Campinas, SP, Brazil
[4] Univ Estadual Campinas, Sch Med Sci, Dept Radiol, Nucl Med Div, Campinas, SP, Brazil
[5] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga, Portugal
[6] ICVS 3Bs PT Govt Associate Lab, Braga Guimaraes, Portugal
[7] Univ Estadual Campinas, Fac Med Sci, Dept Internal Med, Endocrinol Div, Rua Tessalia Vieira Camargo, 126 Cidade Univ, BR-13083887 Campinas, SP, Brazil
来源
基金
巴西圣保罗研究基金会;
关键词
Poorly differentiated thyroid carcinoma; TERT promoter mutation; Molecular marker; CANCER; PREVALENCE;
D O I
10.1016/j.amjms.2023.03.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BRAF and TERT oncogenes hotspot mutations are associated with a more aggressive outcome in thyroid carcinomas (TC). TERT promoter (pTERT) mutations (C228T and C250T) are related to cancer growth and reduced overall-and disease-free survivals in TC. We report a patient followed up for 8 years with a poorly differentiated thyroid carcinoma (PDTC) presenting an extremely aggressive course, who developed a large volume of metastases in a short period. Molecular analysis of the primary tumor revealed two pTERT mutations (C228T and C250T), and no BRAF V600E mutation. pTERT mutations C228T and C250T have been described as mutually exclusive, indicating that one mutation is enough for telomerase activation and exerts its action in thyroid tumorigenesis. This report describes both pTERT hotspot mutations in the same PDTC patient presenting a very aggressive course, even for PDTC, suggesting a relationship between the two events. However, more studies are needed to prove this causality.
引用
收藏
页码:532 / 537
页数:6
相关论文
共 50 条
  • [41] Clinical features of poorly differentiated thyroid papillary carcinoma
    Higashino, Masaaki
    Ayani, Yusuke
    Terada, Tetsuya
    Kurisu, Yoshitaka
    Hirose, Yoshinobu
    Kawata, Ryo
    AURIS NASUS LARYNX, 2019, 46 (03) : 437 - 442
  • [42] Poorly differentiated thyroid carcinoma -: It is important -: Authors' reply
    Nishida, T
    Katayama, S
    Tsujimoto, M
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (02) : 312 - 313
  • [43] Definition of poorly differentiated carcinoma of the thyroid: The Japanese experience
    Atsuhiko Sakamoto
    Endocrine Pathology, 2004, 15 : 307 - 311
  • [44] Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma
    Xu, Bin
    Ghossein, Ronald
    ENDOCRINE PATHOLOGY, 2016, 27 (03) : 205 - 212
  • [45] Poorly Differentiated Thyroid Carcinoma Arising in Struma Ovarii
    Khunamornpong, Surapan
    Settakorn, Jongkolnee
    Sukpan, Kornkanok
    Suprasert, Prapaporn
    Siriaunkgul, Sumalee
    CASE REPORTS IN PATHOLOGY, 2015, 2015
  • [46] Poorly differentiated thyroid carcinoma. An underdiagnosed entity
    Dettmer, M. S.
    Schmitt, A.
    Komminoth, P.
    Perren, A.
    PATHOLOGE, 2019, 40 (03): : 227 - 234
  • [47] Pediatric Poorly Differentiated Thyroid Carcinoma: A Clinicopathologic Study
    Aqil, Barina
    Mehrad, Mitra
    Chernock, Rebecca
    LABORATORY INVESTIGATION, 2017, 97 : 144A - 145A
  • [48] Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
    Roque, Joao
    Silva, Tiago Nunes
    Regala, Catarina
    Rodrigues, Ricardo
    Leite, Valeriano
    EUROPEAN THYROID JOURNAL, 2023, 12 (02)
  • [49] The Concepts in Poorly Differentiated Carcinoma of the Thyroid: A Review Article
    Nambiar, Ajit
    Pv, Sunil
    Susheelan, Vijaylakshmi
    Kuriakose, Moni Abraham
    JOURNAL OF SURGICAL ONCOLOGY, 2011, 103 (08) : 818 - 821
  • [50] Poorly Differentiated Thyroid Carcinoma. Are We There Yet?
    Tallini, Giovanni
    ENDOCRINE PATHOLOGY, 2011, 22 (04) : 190 - 194